Neutrophils superoxide anion generation during carvedilol therapy in patients with stable angina

Jan Kowalski1, Jan Błaszczyk, Edyta Petecka

  • 1Department of Internal Medicine and Cardiological Rehabilitation, Medical University of Łódź, Poland.

Insights

Carvedilol therapy significantly reduced neutrophil superoxide anion generation in stable angina patients. This effect normalized neutrophil function to levels seen in healthy individuals after 8-12 weeks of treatment.

Area of Science:

  • Cardiology
  • Immunology
  • Pharmacology

Background:

  • Neutrophil superoxide anion (O(2)(*-)) generation is elevated in patients with stable angina.
  • This heightened activity may contribute to the pathophysiology of the condition.

Purpose of the Study:

  • To investigate the effect of carvedilol therapy on neutrophil O(2)(*-) generation in patients with stable angina.
  • To compare neutrophil function in patients undergoing treatment with healthy controls.

Main Methods:

  • A randomized controlled study involving 27 stable angina patients treated with escalating doses of carvedilol (12.5-50 mg/day) and 12 healthy controls.
  • Neutrophil O(2)(*-) generation was measured in whole blood, both unstimulated and stimulated with opsonized zymosan (OZ), at baseline and at 4, 8, and 12 weeks post-therapy.
  • Measurements utilized the Bellavite et al. method with bovine erythrocyte superoxide dismutase.

Main Results:

  • Patients with stable angina exhibited significantly higher neutrophil O(2)(*-) generation compared to healthy controls (p<0.05).
  • Carvedilol treatment led to a statistically significant reduction in neutrophil O(2)(*-) generation by 8 and 12 weeks (p<0.05).
  • Following 8 and 12 weeks of carvedilol therapy, neutrophil O(2)(*-) generation in patients returned to levels comparable to those in healthy subjects.

Conclusions:

  • Carvedilol effectively inhibits neutrophil O(2)(*-) generation in patients suffering from stable angina.
  • The therapeutic action of carvedilol may involve the modulation of neutrophil oxidative stress, contributing to its beneficial effects in stable angina.

Related Concept Videos

Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Antianginal Drugs: Nitrates and &#946;-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...